Journal article
Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia
Abstract
BACKGROUND: Rituximab may cause reactivation of hepatitis B virus (HBV) even in patients with remote HBV infection. Thus, the presence of hepatitis B core antibodies (anti-HBc) was an exclusion criterion for a randomized trial of rituximab for patients with immune thrombocytopenia. A high seroprevalence of anti-HBc observed among patients screened for the trial prompted this substudy to investigate for an association between anti-HBc …
Authors
Arnold DM; Crowther MA; Meyer RM; Carruthers J; DiTomasso J; Heddle NM; McLeod A; Kelton JG
Journal
Transfusion, Vol. 50, No. 12, pp. 2577–2581
Publisher
Wiley
Publication Date
December 2010
DOI
10.1111/j.1537-2995.2010.02766.x
ISSN
0041-1132
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAntibodies, Monoclonal, Murine-DerivedCase-Control StudiesDiagnostic ErrorsFemaleHepatitis BHepatitis B AntibodiesHumansImmunoglobulins, IntravenousImmunologic FactorsMalePurpura, Thrombocytopenic, IdiopathicRandomized Controlled Trials as TopicResearch DesignRetrospective StudiesRituximabSerologic Tests